Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Diseaseopen accessReal-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease
- Other Titles
- Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease
- Authors
- 백종하; 양예슬; 고승현; 한경도; 김재현; 문민경; 박종석; 이병완; 오태정; 전숙; 최종한; 허규연
- Issue Date
- Sep-2022
- Publisher
- 대한당뇨병학회
- Keywords
- Asians; Cardiovascular diseases; Diabetes mellitus; type 2; Healthcare disparities; Heart failure; Sodium-glucose transporter 2 inhibitors
- Citation
- Diabetes and Metabolism Journal, v.46, no.5, pp.701 - 712
- Journal Title
- Diabetes and Metabolism Journal
- Volume
- 46
- Number
- 5
- Start Page
- 701
- End Page
- 712
- URI
- http://scholarworks.bwise.kr/ssu/handle/2018.sw.ssu/43188
- DOI
- 10.4093/dmj.2022.0002
- ISSN
- 2233-6079
- Abstract
- Background: To evaluate prescription trends and clinical factors of the sodium-glucose cotransporter 2 inhibitors (SGLT2i) use according to the presence of atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF) in Korean patients with type 2 diabetes mellitus (T2DM).Methods: Prescription patterns of SGLT2i use between 2015 and 2019 were determined using the Korean National Health Insurance Service database of claims.Results: Of all patients with T2DM (<i>n</i>=4,736,493), the annual prescription rate of SGLT2i increased every year in patients with ASCVD (from 2.2% to 10.7%) or HF (from 2.0% to 11.1%). After the first hospitalization for ASCVD (<i>n</i>=518,572), 13.7% (<i>n</i>=71,259) of patients initiated SGLT2i with a median of 10.6 months. After hospitalization for HF (<i>n</i>=372,853), 11.2% (<i>n</i>=41,717) of patients initiated SGLT2i after a median of 8.8 months. In multivariate regression for hospitalization, older age (per 10 years, odds ratio [OR], 0.57; 95% confidence interval [CI], 0.56 to 0.57), lower household income (OR, 0.93; 95% CI, 0.92 to 0.95), rural residents (OR, 0.95; 95% CI, 0.93 to 0.97), and dipeptidyl peptidase-4 inhibitor (DPP-4i) users (OR, 0.82; 95% CI, 0.81 to 0.84) were associated with lesser initiation of SGLT2i in ASCVD. Additionally, female gender (OR, 0.97; 95% CI, 0.95 to 0.99) was associated with lesser initiation of SGLT2i in HF.Conclusion: The prescription rate of SGLT2i increased gradually up to 2019 but was suboptimal in patients with ASCVD or HF. After the first hospitalization for ASCVD or HF, older age, female gender, low household income, rural residents, and DPP-4i users were less likely to initiate SGLT2i.
- Files in This Item
-
Go to Link
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/ssu/handle/2018.sw.ssu/43188)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.